These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 23820059)

  • 41. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
    Schröder FH; Bangma CH; Wolff JM; Alcaraz A; Montorsi F; Mongiat-Artus P; Abrahamsson PA; McNicholas TA; Castro RS; Nandy IM
    BJU Int; 2009 Mar; 103(5):590-6. PubMed ID: 19226424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.
    Nickel JC; Roehrborn C; Montorsi F; Wilson TH; Rittmaster RS
    J Urol; 2011 Oct; 186(4):1313-8. PubMed ID: 21849186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M; Fleshner NE; Finelli A; Zlotta AR
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.
    Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED
    J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
    Tosoian JJ; Loeb S; Kettermann A; Landis P; Elliot DJ; Epstein JI; Partin AW; Carter HB; Sokoll LJ
    J Urol; 2010 Feb; 183(2):534-8. PubMed ID: 20006883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate-specific antigen velocity in untreated, localized prostate cancer.
    Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
    BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
    Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
    Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.
    van Leeuwen PJ; Kölble K; Huland H; Hambrock T; Barentsz J; Schröder FH
    Eur Urol; 2011 Feb; 59(2):183-90. PubMed ID: 21130560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.
    Dinh KT; Mahal BA; Ziehr DR; Muralidhar V; Chen YW; Viswanathan VB; Nezolosky MD; Beard CJ; Choueiri TK; Martin NE; Orio PF; Sweeney CJ; Trinh QD; Nguyen PL
    J Urol; 2015 Aug; 194(2):343-9. PubMed ID: 25681290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study.
    Scholz MC; Groom MK; Kaddis AJ; Strum SB; Jennrich RI; Bahn DK; Chang PJ; Becker LK; Lam RY
    Prostate; 2013 Jan; 73(1):83-8. PubMed ID: 22753276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
    Finelli A; Trottier G; Lawrentschuk N; Sowerby R; Zlotta AR; Radomski L; Timilshina N; Evans A; van der Kwast TH; Toi A; Jewett MA; Trachtenberg J; Fleshner NE
    Eur Urol; 2011 Apr; 59(4):509-14. PubMed ID: 21211899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.